Results 81 to 90 of about 66,449 (275)

Elevated PAF1-RAD52 axis confers chemoresistance to human cancers

Cell Reports, 2023
Summary: Cisplatin- and gemcitabine-based chemotherapeutics represent a mainstay of cancer therapy for most solid tumors; however, resistance limits their curative potential.
Sanchita Rauth, Koelina Ganguly, Pranita Atri, Seema Parte, Rama Krishna Nimmakayala, Venkatesh Varadharaj, Palanisamy Nallasamy, Raghupathy Vengoji, Ayoola O. Ogunleye, Imayavaramban Lakshmanan, Ramakanth Chirravuri, Mika Bessho, Jesse L. Cox, Jason M. Foster, Geoffrey A. Talmon, Tadayoshi Bessho, Apar Kishor Ganti, Surinder K. Batra, Moorthy P. Ponnusamy   +18 more
doaj   +1 more source

Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity [PDF]

, 2016
BACKGROUND: Lung cancer is the leading cause of cancer related deaths and Malignant Pleural Effusion (MPE) is a frequent complication. Current therapies suffer from lack of efficacy in a great percentage of cases, especially when cancer is diagnosed at ...
CHERUBINI, EMANUELA, DE VITIS, CLAUDIA, Fabiana Fosca Ferrara, Francesca Bergantino, Francesca Fenizia, Gennaro Ciliberto, GIARNIERI, Enrico, GIOVAGNOLI, Maria Rosaria, Luigi Aurisicchio, MANCINI, RITA, MARIOTTA, Salvatore, Matilde Lambiase, Nicola Normanno, NOTO, ALESSIA, RICCI, Alberto, ROSCILLI, GIUSEPPE, Susan Costantini, TORRISI, Maria Rosaria   +17 more
core   +3 more sources

Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity [PDF]

Acta Pharmacologica Sinica, 2009
To investigate whether aspirin is able to augment gemcitabine-induced cytotoxicity in human pancreatic cancer cells.Two gemcitabine-insensitive human pancreatic cancer cell lines, PANC-1 and Capan-1, were used. Cells were treated with either aspirin or gemcitabine alone or both of them.
Yan-qiu, Ou, Wen bo, Zhu, Yan, Li, Peng-xin, Qiu, Yi-jun, Huang, Jun, Xie, Song-min, He, Xiao-ke, Zheng, Tian-dong, Leng, Dong, Xu, Guang-mei, Yan   +10 more
openaire   +2 more sources

Metabologenomic Hallmark‐Based Discovery of Bacterial Thioamides as a New Lead against Drug‐Resistant Pancreatic Cancer

Advanced Science, EarlyView.
A targeted metabologenomic strategy integrating genomic and metabolomic hallmarks enabled the discovery of two new thioamides, thiogochangamides A and B, from bacteria. Their absolute configurations, previously unresolved within the thioviridamide family, were fully assigned through various chemical derivatizations and computational analysis ...
Young Eun Du, Eun Seo Bae, Thinh T. M. Bui, Seok Beom Lee, Dahan Kim, Jin‐Gyeong Park, Yongjoo Park, Soo Yeon Park, Sangwook Kang, Beomsu Lee, Daniel Shin, Yun Pyo Kang, In‐Gyun Lee, Dae‐Duk Kim, Seokhee Kim, Suckchang Hong, Kyuho Moon, Sang Kook Lee, Dong‐Chan Oh   +18 more
wiley   +1 more source

Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts. [PDF]

, 2019
Pancreatic cancer is a complex disease, in need of new therapeutic approaches. In this study, we explored the effect and mechanism of action of epigallocatechin-3-gallate (EGCG), a major polyphenol in green tea, alone and in combination with current ...
Hackman, Robert M, Mackenzie, Gerardo G, Wang, Yuefei, Wei, Ran   +3 more
core   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells [PDF]

, 2015
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and incurable disease. Poor prognosis is due to multiple reasons, including acquisition of resistance to gemcitabine, the first-line chemotherapeutic approach.
Bielli, P, Calabretta, S, Capurso, G, DELLE FAVE, Gianfranco, Fendrich, V, Passacantilli, I, Pilozzi, Emanuela, Sette, C.   +7 more
core   +2 more sources

Targeting m6A Reader YTHDF1 Enhances Antitumor Immunity and Potentiates Anti‐PD‐L1 Efficacy in Intrahepatic Cholangiocarcinoma

Advanced Science, EarlyView.
The m6A reader YTHDF1 drives intrahepatic cholangiocarcinoma (ICC) progression by remodeling the tumor immune microenvironment. YTHDF1 promotes MDSC recruitment via activation of m6A‐FOSL2‐CXCL6/CXCR2 axis, thereby suppressing CD8+ T cell infiltration and function.
Li Luo, Ziqin Liu, Zimin Song, Dong Zhang, Cong Liang, Fei Fang, Kai Lei, Lina Wang, Weikang Chen, Shunli Shen, Ming Kuang, Xiaoxing Li, Jun Yu, Shiyan Wang, Lixia Xu   +14 more
wiley   +1 more source

mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer

Neoplasia: An International Journal for Oncology Research, 2021
Ribonucleotide reductase (RNR) is the key enzyme that catalyzes the production of deoxyribonucleotides (dNTPs) for DNA replication and it is also essential for cancer cell proliferation.
Ling Tian, Congcong Chen, Yanguan Guo, Fan Zhang, Jinye Mi, Qi Feng, Shengbin Lin, Naite Xi, Jiaxin Tian, Li Yu, Yan Chen, Mingrong Cao, Caiyong Lai, Jun Fan, Yongchang Zhang, Guo Chen   +15 more
doaj   +1 more source

Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance [PDF]

Cancer Research, 2019
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer deaths in the United States. The deoxynucleoside analogue gemcitabine is among the most effective therapies to treat PDAC, however, nearly all patients treated with gemcitabine either fail to respond or rapidly ...
Simona Dalin, Mark R. Sullivan, Allison N. Lau, Beatrice Grauman-Boss, Helen S. Mueller, Emanuel Kreidl, Silvia Fenoglio, Alba Luengo, Jacqueline A. Lees, Matthew G. Vander Heiden, Douglas A. Lauffenburger, Michael T. Hemann   +11 more
openaire   +2 more sources